Wash U, Partners Kick off Five-Year Warfarin PGx Dosing Trial | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A group of hospitals led by Washington University School of Medicine in St. Louis has begun a clinical trial to determine how well genetic variants can customize dosing for the blood thinner warfarin.

The National Heart, Lung, and Blood Institute is funding the five-year, $3.7 million Genetics Informatics Trial of Warfarin, or GIFT, which will test a warfarin-dosing formula that takes three genetic variants into account.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.